Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mink Therapeutics Inc INKT

Healthcare Biotechnology
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells... see more

Recent & Breaking News (NDAQ:INKT)

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

GlobeNewswire 11 days ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

GlobeNewswire November 11, 2024

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

GlobeNewswire November 7, 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

GlobeNewswire October 31, 2024

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

GlobeNewswire October 8, 2024

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

GlobeNewswire October 4, 2024

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

GlobeNewswire September 3, 2024

MiNK Reports Second Quarter 2024 Results and Business Update

GlobeNewswire August 13, 2024

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

GlobeNewswire August 1, 2024

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

GlobeNewswire July 31, 2024

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

GlobeNewswire June 5, 2024

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

GlobeNewswire May 22, 2024

MiNK Reports First Quarter 2024 Results

GlobeNewswire May 14, 2024

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

GlobeNewswire May 13, 2024

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

GlobeNewswire April 30, 2024

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

GlobeNewswire April 8, 2024

MiNK Reports Fourth Quarter and Year-End 2023 Results

GlobeNewswire March 21, 2024

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

GlobeNewswire March 7, 2024

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

GlobeNewswire March 6, 2024

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab

GlobeNewswire February 14, 2024